Skip to content

Advertisement

BMC Cancer

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Genistein induces apoptosis of colon cancer cells by reversal of epithelial-to-mesenchymal via a Notch1/NF-κB/slug/E-cadherin pathway

  • Panpan Zhou1, 2,
  • Chunling Wang2,
  • Zebin Hu3,
  • Wenruo Chen1,
  • Wentao Qi1Email author and
  • Aike Li1
BMC Cancer201717:813

https://doi.org/10.1186/s12885-017-3829-9

Received: 9 August 2017

Accepted: 23 November 2017

Published: 4 December 2017

Abstract

Background

Genistein has been known to inhibit proliferation and induce apoptosis in several kinds of cancer cells. While knowledge of genistein in regulating epithelial mesenchymal transition (EMT) of colon cancer cells is unknown.

Methods

To investigate the effects and mechanisms of genistein on EMT of colon cancer cells, HT-29 cells were used and treated by genistein and TNF-α in this paper. EMT was determined by cell invasion assays using a transwell chamber and the expression changes of EMT-related markers were confirmed by RT–PCR, Western blotting, and immunofluorescence staining.

Results

Genistein inhibited cell migration at 200 μmol/L. Genistein reversed the EMT of colon cancer cells by upregulation of E-cadherin and downregulation of N-cadherin, accompanied by the suppression of EMT related makers, such as Snail2/slug, ZEB1, ZEB2, FOXC1, FOXC2 and TWIST1. Moreover, genistein can inhibit the expression of notch-1, p-NF-κB and NF-κB, while promote the expression of Bax/Bcl-2 and caspase-3 in HT-29 cells.

Conclusion

The present study demonstrated that genistein suppressed the migration of colon cancer cells by reversal the EMT via suppressing the Notch1/NF-κB/slug/E-cadherin pathway. Genistein may be developed as a potential antimetastasis agent to colon cancer.

Keywords

GenisteinColon cancer cellApoptosisEpithelial mesenchymal transition

Background

Colon cancer, a deadly disease, is the third most common cancer type in males, and the second most common cancer type in females, with a global incidence of 1,360,000 cases and 694,000 deaths in 2012 [1]. It may be caused by many risk factors such as social environment, lifestyle especially eating habits, lack of physical activity, genetic factors etc. [2, 3]. Genistein (GEN), a potential cancer chemopreventive agent, is one of the active ingredients of soy isoflavones and has been reported to possess various biological activities, such as anti-tumor, antibacterial, lipid-lowering, estrogen-like effect [47]. In vitro data has shown that GEN can inhibit the growth of several colon cancer cells [8], while its particular effects on cancer cells and the mechanisms involved remain unknown [9, 10].

Epithelial mesenchymal transition (EMT) is an important process during tumor progression which affects critical steps of morphogenesis by interconverting epithelial cell types into cells with mesenchymal attributes [11]. Tumor necrosis factor-α (TNF-α) has been considered stimulated the EMT in several kinds of cancer cells which is a function that contrasts with its more established role in inducing apoptosis [7, 12, 13]. When EMT was happened, the expression of E-cadherin was found decreased, while N-cadherin, vimentin and other interstitial markers were increased, at the same time, EMT-associated transcription factor, such as Snail, Slug, ZEB1/2, Twist1/2 were upregulated [1315].

Increasing evidence emphasizes a critical role of EMT endowing the incipient cancer cell with invasive and metastatic properties [16]. Apoptosis, which is a major way of programmed cell death, has been known to all plays an important role in the regulation of tissue development and homeostasis [17]. In recent years, the role of EMT in cell apoptosis has received considerable attention [18, 19]. It is considered that the induction of apoptotic cell death and reversal of EMT are promising emerging strategy for prevention and treatment of cancer [20, 21].

Genistein was found can induce the reversal of EMT in prostate cancer cells by an upregulated expression of epithelial marker E-cadherin and the loss of expression of mesenchymal marker vimentin [22]. GEN was also suggested can inhibit cell migration and invasion in both AsPC-1 and Notch-1-over-expressed AsPC-1 cells as Notch-1 could play a key role in the regulation of EMT [23]. However, current knowledge of GEN in regulating EMT of colon cancer cells is limited, and more detailed investigations of its function and mechanism are required.

Our previous study has proved GEN inhibits EGF-induced proliferation in colon cancer cells by promoting FOXO3 activity, targeting upstream the PI3K/Akt pathway [3]. In this study, we demonstrated that GEN can inhibite proliferation and induce apoptosis of colon cancer cells by reversal of EMT via a Notch1/NF-κB/Slug/E-cadherin pathway. This study demonstrates a new anti-tumor mechanism of genistein mediated by inhibiting the process of EMT in colon cancer cells.

Methods

Cell culture

HT-29 (ATCC number: HTB-38) colon cancer cells (ATCC (American Type Culture Collection), Manassas, VA) were cultured in RPMI-1640 medium (GIBCO) containing 10% FBS (Gibco), 100 U/mL penicillin and 100 U/mL streptomycin, at 37 °C and 5% CO2.

Treatment

To examine the effects of GEN on proliferation, cells were loaded on 96-well plates for overnight and then changed to medium contained with 25–400 μmol/L GEN (LC Laboratories, Woburn, MA) respectively for another 48 h. To examine the effects of GEN on EMT, overnight monolayers were treated with medium added by GEN (200 μmol/L) and TNF-α (10 ng/mL) (Sigma-Aldrich) respectively for another 48 h. During the treatment, cells were placed in serum-free and antibiotic-free medium.

Cell proliferation

An inhibitory effect of GEN on proliferation of colon cancer cell lines was evaluated by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium) assay. HT-29 cells were plated in 96-well plates (5000 cells per well). After incubation for 24 h, various concentrations of GEN were added into each well and each concentration was repeated in five wells. After 48 h incubation, the medium was aspirated and 0.5 μg/mL MTT was added. Cells were incubated at 37 °C for another 4 h and the formazan product was solubilized with dimethylsulfoxide (DMSO). The optical density (OD) of each well was then measured at 570 nm on an enzyme linked immunosorbent assay (ELISA) microplate reader (Multiskan EX, Labsystems, Helsinki, Finland). Each test was performed in triplicate experiments.

Flow cytometry analysis

HT-29 cells were seeded in a 6-well plate and treated with 200 μmol/L GEN for 48 h, then cells were collected and washed with cold PBS, After fixing by ethanol (70%, v/v). Cells were dissolved in PBS (containing PI, RNase, EDTA and Triton X-100, pH 7.4) and incubated at 37 °C for 30 min, followed by incubation at 4 °C for 1 h in the dark. Finally, the samples were detected with a flow cytometry (Becton, Dickinson, USA).

DAPI staining

The levels of nuclear condensation and fragmentation were observed by means of nucleic acid staining with DAPI (4′,6-diamidino-2-phenylindole) (Solarbio, Beijing, China). Briefly, HT-29 cells were plated in 6-well plates (105 cells per well). After treatment, the cells were washed twice with PBS, and were fixed with methanol (MeOH), acetic acid (HAc) (3:1, v/v) for 10 min at 4 °C. Cells were stained with DAPI (10 mg/mL) for 20 min in the dark, and were then observed under a fluorescence microscope (Olympus BX41, Japan) in less than 15 min.

AO/EB staining

Acridine orange and ethidium bromide (AO/EB) staining (Solarbio, Beijing, China) was carried out to further prove the cell apoptosis. Briefly, HT-29 cells were plated in 6-well plates (105 cells per well). After treatment, Cells were washed with PBS for three times and then stained with the staining solution containing 100 μg/mL acridine orange and 100 μg/mL ethidium bromide for 20 min at room temperature in the dark. Cells were observed under an inverted fluorescence microscope (Olympus BX41, Japan) after the staining.

Cell invasion assays using a transwell chamber

Cell invasion assays were performed using a Transwell chamber (8.0 μm, Polycarbonate, Corning, USA). Transwell chambers were precoated with Matrigel (1: 8; BD, Bedford, MA, USA) and exposed to ultraviolet light for 2 h following air-drying at 4 °C. Transwell chambers were then inserted into a 24-well plate containing culture medium with 20% FBS in lower chamber. Cells were starved overnight and then seeded on the upper chamber (1 × 105 cells per well in 0.4% FBS culture medium). After incubation for 24 h, the filter inserts were removed from the wells and the cells on the upper side of the filter were removed using cotton swabs. Cells invaded to the underside of the filter were first fixed with methanol (15 min), and then stained with 2% ethanol containing 0.1% crystal violet powder (15 min). After being dried, the stained cells were enumerated under a microscope (Olympus BX41, Japan).

Immunofluorescence imaging of E-cadherin

Briefly, the cell suspension (1 × 105/mL) was inoculated on cover slips which were partitioned previously into the wells of a 6-well plate. After 24 h, HT-29 cells were treated with 200 μmol/mL GEN and 10 ng/mL TNF-α respectively for 48 h. Cells were fixed with 3% formaldehyde in phosphate buffered saline (PBS, pH 7.4) for 20 min, and washed thrice with PBS. Washed cells were permeabilized using 0.2% Triton X-100 and blocked in 2% BSA in PBS. Then cells were washed thrice with PBS, and incubated with the antibody E-cadherin (dilution 1:200) with 2% BSA in PBS at 37 °C for 1 h. The resulting cells were washed thrice with PBS and incubated with fluorescein FITC- labeled polyclonal goat anti-mouse IgG antibody (dilution 1:200) at 37 °C for 1 h. Cells were stained with propidium iodide (DAPI) (Sigma) and scanned by LSCM. All images were acquired using the same intensity and photodetector gain.

Protein extraction and immunoblot

Experimental monolayers were washed with serum free media, and then total and fractionated proteins were extracted by cell lysis buffer (Cell Signaling Technology, Danvers, MA). The lysates were centrifuged at 12,000×g for 20 min at 4 °C. Equal amounts of protein, after concentration was determined by the Bradford assay (Bio-Rad, Hercules, CA), were loaded on SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad). After blocking, specific antibodies such as Bax, caspase-3, caspase-8, Bcl-2, PI3K, Notch1, p-NF-κB, NF-κB, E-cadherin, N-cadherin and β-actin from AB clonal Biotechnology Co., Ltd. (Wuhan, China) were used to perform detection. Finally each protein was detected using an enhanced chemilumi-nescence system (GE Healthcare, USA). Blot images were digitized (Chemidoc, Bio-Rad, Milan, Italy) and the area of each band was quantified using the computerized imaging system (QuantityOne, Bio-Rad). Relative optical density (arbitrary units) was normalized for control bands in each series and for protein loading (as probed by anti-actin blots). Each test was performed in triplicate experiments.

RT-PCR procedure

Total cellular RNA was extracted using the trizol reagent (TransGen Biotech, Beijing, China) according to manufacturer’s instructions. One microgram of total RNA was reverse transcribed at 42 °C for 50 min using a TransScript First-Strand cDNA Synthesis SuperMix according to manufacturer’s instructions (TransGen Biotech, Beijing, China). PCR was then performed using Taq (TaKaRa, Shiga, Japan) polymerase. Each amplification was performed for 35 cycles, one cycle profile consisted of denaturation at 94 °C for 30 s, annealing at 55 °C for 30 s and extension at 72 °C for 120 s. PCR products were visualized by eletrophoresis through 1.2% agarose gels and quantifed with Glyko Bandscan gel analyzing software (Glyko, Novato, CA, USA). Parallel reactions were run using human GAPDH as a control for RT–PCR. The primer sequences that used for RT-PCR of slug, twist1, zeb1, zeb2, foxc1, foxc2 [2427] and GAPDH were shown in Table 1.
Table 1

Primer sequences used for RT-PCR

Name

Forward primer

Reverse primer

Product size (bp)

slug

GCTACCCAAGGCCTCTCTC

GCCCAGGGCTTCATTGTATCT

478

twist1

CAGCCACTGAAAGGAAAGGC

CCTCCTGGGTGCCTCTAGAAT

418

zeb1

TGATCTGGCCATTTTCACCTGT

GACTTGCCAGGACAGCTTGC

306

zeb2

CACAGGTATGAGTGACTTTGCC

TGGCTGTGTCATGCCATTTC

302

foxc1

ATGTTCGAGTCACAGAGGATCG

TGGTGCTGGTGAGCTGAAT

305

foxc2

CGCCCGAGAAGAAGATCACC

CGCTCTTGATCACCACCTTC

384

GAPDH

GGACTCATGGTATGAGAGCTGG

GATGGCATGGACTGTGGTCT

220

Statistical analysis

The experiments were repeated three times and the mean values were analyzed by a two-tailed unpaired t-test. The results were expressed as mean ± SD. All statistical tests were performed with statistical analysis software (SPSS, Chicago, IL, USA). The level of p < 0.05 was considered to be statistically significant.

Results

Genistein inhibit proliferation and induce apoptosis of HT-29 cells

HT-29 cells were cultured with the indicated concentrations of GEN for 48 h, and cell viability was determined by MTT assay. The result showed that GEN inhibited the growth of HT-29 cells in a dose-dependent manner, with the best inhibition at 48 h in a concentration of 200 μmol/L (Fig. 1a). And the dose-dependent increase of inhibition ratio were suppressed when the concentration of GEN were over 200 μmol/L. The DAPI and AO/EB staining suggested that cell apoptosis can be significantly induced by GEN at 48 h with a concentration of 200 μmol/L (Fig. 1b). The cell-cycle phase distribution and the ratios of apoptotic cells were further determined by flow cytometry with PI staining. The percentage of cells in G1, S and G2/M phase was evaluated using Multi-cycle software, respectively. The results showed a significant increase of GEN treated cells in the G0/G1 phase from 44.60 ± 3.32% to 58.51 ± 9.20 (p < 0.05) compared with control, and the apoptotic rate increased significantly (p < 0.05) from 2.49 ± 0.16% to 21.50 ± 8.50% (Fig. 1c). These data indicated that GEN can induce apoptosis of HT-29 cells significantly at 200 μmol/L for 48 h. Thus, all the treatments of cells in the following experiment were carried out with 48 h of 200 μmol/L GEN.
Fig. 1

Genistein inhibit proliferation and induce apoptosis of HT-29 cells. a Genistein inhibited the proliferation of HT-29 cells in a dose-dependent manner. The inhibition ratio of proliferation could be up to 46 ± 1.2% at the concentration of 200 μmol/L for 48 h (n = 6). b Morphological evidence of apoptosis in HT-29 cells after 48 h of 200 μmol/L GEN treatment by DAPI and AO/EB staining. The stained nuclei were observed under a laser confocal fluorescence microscope, bar = 50 μm (×400). And the percentage of apoptotic cells per field were calculated in 3 different fields and represented by graphs (*p < 0.05, vs control). c Cell cycle distribution and apoptosis rate of HT-29 cells by flow cytometry after treatment with genistein (200 μmol/L) and daidzein (200 μmol/L) respectively for 48 h. (*p < 0.05, n = 3, vs control)

Genistein inhibit invasion ability of HT-29 cells

GEN was confirmed in this paper inhibit proliferation and induce apoptosis of colon cancer cells in vitro. We next characterize the effect of GEN on cell invasion in HT-29 cells by transwell chamber assay with TNF-α treatment as a positive control, since TNF-α has been proved by several research can induce EMT of kinds of cancer cells [7, 12, 28]. The results showed that few cells moved into the lower chamber of the control group, and there was fewer cells moved into the lower chamber of the GEN group, and there was significant decrease compared with control group (n = 3, p < 0.05), while the number of cells that moved into the lower chamber of the TNF-α was significantly higher than that of the control group and GEN group (p < 0.01). These results indicated that the invasion ability of the HT-29 cells in GEN group was significantly reduced than in the control and TNF-α group (Fig. 2a and b).
Fig. 2

Genistein inhibit invasion ability of HT-29 cells. a Comparison of the cells moved into the lower chamber in each group. b Number of invasion cells per field were quantified in 5 different fields and represented by graphs, bar = 50 μm (*p < 0.05, **p < 0.01 vs control)

Genistein induced reversal of EMT in HT-29 cells

To further characterize the reversal of EMT induced by GEN, we analyzed the effect of GEN on EMT-related markers, E-cadherin and N-cadherin, using immunofluorescence staining and western blot assay. The Immunofluorescence results showed that the intensity of E-cadherin signal treated by GEN was obviously stronger than that of the TNF-α and control group (Fig. 3a). And the percentage of E-cadherin positive cells was 79.41 ± 12.59% in GEN group, significantly higher (p < 0.05) than 19.37 ± 2.94% in control group and 7.56 ± 2.50% in TNF-α group (Fig. 3b). Western-blot results further showed that TNF-α significantly reduced the E-cadherin expression (p < 0.05) and increased the expression of N-cadherin (p < 0.05) which suggested a positive effect of TNF-α on EMT (Fig. 3c). However, in parallel with the marked increase in the E-cadherin expression (p < 0.01), GEN significantly decreased the expression of N-cadherin (p < 0.01) within 48 h (Fig. 3c). These data suggested that GEN can reverse the EMT of HT-29 cells.
Fig. 3

Effect of genistein and TNF-α on EMT-related markers, E/N-cadherin in HT-29 cells. a the protein expressions of E-cadherin in the cells treated with genistein (200 μmol/L) and TNF-α (10 ng/mL) respectively for 48 h were examined by immunofluorescence staining, bar = 50 μm (×400). b The percentage of E-cadherin positive cells per field were calculated in 3 different fields and represented by graphs (**p < 0.01, vs control). c Western blot analysis of E/N-cadherin expression in the cells treated by genistein (200 μmol/L) and TNF-α (10 ng/mL) respectively for 48 h. Density of the bands were quantified by a densitometry analysis. Data are presented after normalization by β-actin. The data shown are representative of three independent experiments. (*p < 0.05, **p < 0.01 vs control)

Effects of genistein on the mRNA expression of invasion-related genes in HT-29 cells

In addition to the changes of EMT markers, the mRNA expressions of invasion-related genes in the cells were also evaluated using RT–PCR assay. The results showed that GEN significantly decreased the mRNA expression of slug, zeb1, zeb2, foxc-1, foxc-2 and twist1 in HT-29 cells (p < 0.05) (Fig. 4). While TNF-α significantly increased the mRNA expression of zeb1. Marked increases of the mRNA expression of slug, zeb2 and twist1 didn’t found, and fox-1 and fox-2 mRNA expression were even lower than control group. But all these mRNA expressions were significantly higher than GEN group (p < 0.05) (Fig. 4). These data demonstrates that GEN can significantly inhibit mRNA expression of invasion-related genes in HT-29 cells.
Fig. 4

Effect of genistein and TNF-α on mRNA expression of invasion-related genes in HT-29 cells. Slug, zeb1, zeb2, foxc-1, foxc-2 and twist1 expressions in the cells treated with genistein (200 μmol/L) and TNF-α (10 ng/mL) respectively for 48 h were determined by RT-PCR analysis. Quantification of the mRNA were normalized by GAPDH. Genistein treatment leads to decreased invasion-related genes expression. The data shown are representative of three independent experiments. (*p < 0.05 vs control, # p < 0.01 vs GEN group)

Genistein inhibited the protein expression of NF-κB and p-NF-κB in HT-29 cells

NF-κB has been found represses E-cadherin expression and enhances EMT of several kinds of cancer cells [2931]. TNF-α can induce the EMT via the NF-κB pathway [32]. We found in this paper, GEN significantly down-regulated the expression of both NF-κB p65 and p-NF-κB p65 (p < 0.05) (Fig. 5). However, exposure to TNF-α resulted in remarkable increase of NF-κB p65 and p-NF-κB p65 (p < 0.05) (Fig. 5). These results suggested that GEN can reverse EMT through NF-κB pathway in HT-29 cells.
Fig. 5

The role of NF-κB p65 in genistein induced reversal of EMT in HT-29 cells. Western blot analysis were carried out to demonstrated the of expression NF-κB p65 and phosphorylation NF-κB p65 in the cells treated by genistein (200 μmol/L) and TNF-α (10 ng/mL) respectively for 48 h. Density of the bands were quantified by a densitometry analysis. Genistein treatment leads to the decrease of both NF-κB p65 and p-NF-κB p65 expressions. Data are presented after normalization by β-actin. The data shown are representative of three independent experiments. (*p < 0.05, vs control; # p < 0.05, vs GEN group)

Genistein reduce the protein expression of Notch-1 and induce the expression of Bax/Bcl-2, Caspase-8 and Caspase-3 in HT-29 cells

In addition, we found that GEN significantly inhibited the expression of both notch-1 (p < 0.05) (Fig. 6). TNF-α significantly reduced the level of notch-1 expression, however, the level was significantly higher when compared with GEN treatment (p < 0.05) (Fig. 6). It has been confirmed that the genes such as anti-apoptotic (B-cell lymphoma-2, Bcl-2) and pro-apoptotic (Bax) are important regulators of apoptosis in colon cancer cell lines [3335]. And Caspases play a central role in apoptosis-induction [36]. Here our results showed that GEN significantly increase the expression of all the proteins including Bcl-2/Bax, Caspases-8 and Caspases-3 (P < 0.05) (Fig. 6). TNF-α was found also increase the expression of these proteins (p < 0.05), while the levels were lower than GEN conditions except Caspases-3 which no significant difference was found between the two treatments (Fig. 6).
Fig. 6

Genistein reduce the protein expression of Notch-1 and induce the expression of Bax/Bcl-2, Caspase-8. Western blot analysis were carried out to demonstrated the of expression of Notch-1, Bax, Bcl-2 and Caspase-8 in HT-29 cells treated by genistein (200 μmol/L) and TNF-α (10 ng/ml) respectively for 48 h. Density of the bands were quantified by a densitometry analysis. Data are presented after normalization by β-actin. The data shown are representative of three independent experiments. (*p < 0.05, vs control; # p < 0.05, vs & GEN group)

Discussion

Studies of the biological activities of GEN have always been of particular interest. Although GEN has been tested for potential anti-tumor effect, new mechanisms still are waiting for us to understand. The aim of this study was mainly to determine anti-tumor activity according the EMT. Therefore, we firstly confirmed that the exposure of HT-29 cells to GEN in a dose-dependent inhibition of cell proliferation. These results are consistent with several previous studies in HT-29 [37, 38]. Apoptosis is characterized by a series of morphological alterations such as condensation of chromatin, and fragmentation of nuclear [39]. The DAPI and AO/EB staining as well as the FCM results confirmed that GEN can induce significant apoptosis at a concentration of 200 μM for 48 h. And 200 μM was found in this study as the optimum concentration of GEN for inhibiting proliferation and inducing apoptosis.

Recently, EMT has received tremendous attention. EMT is commonly characterized by the downregulation of E-cadherin (a critical cell-to-cell adhesion molecule), and the upregulation of vimentin (a critical role in cell migration) and N-cadherin (involved in a process known as cadherin switching) [40, 41]. In our present research, in parallel with the marked increase in the E-cadherin, GEN significantly decreased the expression of N-cadherin. Immunostaining with antibodies to E-cadherin showed the changes in the localization and expression. These data suggested that GEN can reverse the level of these EMT-related proteins.

EMT is actively involved in tumor invasion and metastasis [24]. We examined the migration ability of the HT-29 cells under different treatments using a transwell chamber. The results demonstrated that the cells treated by TNF-α were more likely to metastasize than the cells treated by GEN and control. (P < 0.05). The cells treated by GEN even showed lower migration ability than control (P < 0.05). These data suggested that GEN can reverse the cells from the mesenchymal phenotype to epithelial phenotype.

TNF-α recently has been found can induce EMT in LIM 1863 cells which is a role that contrasts with its more established function in inducing apoptosis [7]. Our results here again found that TNF-α promoted EMT in HT-29 cells by downregulation of E-cadherin and upregulation of N-cadherin, accompanied by an induction of cell migration ability. These data also may confirmed previously find that TNF-α mRNA transcripts are more abundant in colorectal tumor cells than in their normal epithelial counterparts [7, 42].

Many of the EMT inducing transcription factors such as Snail1, Snail2/slug, ZEB1, ZEB2, FOXC2 and TWIST1 have been associated with tumor invasion and metastasis [24, 43]. We didn’t found significant increase of ZEB1, ZEB2, and TWIST1 mRNA expression when cells were treated by TNF-α, while the mRNA expression of slug and zeb-1 significantly increased suggested an induction of EMT by mRNA expression. The mRNA expression of FOXC1 and FOXC2 were found lower than control. This may be explained by some studies that have found the overexpression of Foxc2 enhances proliferation and inhibits apoptosis through activation of MAPK and AKT pathways in colorectal cancer [44]. On the other hand, our study clearly demonstrated that treatment by GEN decreased the mRNA expression of several mesenchymal cell markers, slug, ZEB1, ZEB2, FOXC1, FOXC2 and TWIST1 which strongly resulted in the reverse of EMT phenotype in HT-29 cells.

The family of nuclear factor-kappaB (NF-κB) transcription factors plays a pivotal role in adjusting gene transcription and governs cellular apoptosis and proliferation [45, 46]. In most normal cell, NF-κB is in an inactive form and retains in the cytoplasm which can be positively induced by TNF-α [46, 47]. NF-κB has been improved by reports can enhances EMT by repressing the expression of E-cadherin and regulation the mRNA expression of snail and zeb [29, 48]. Our data showed that GEN significantly decreased the expression of p-NF-κB and NF-κB by 25 ± 0.05% and 19 ± 0.06% respectively when compared with control (P < 0.05). On the opposite was the increase of p-NF-κB and NF-κB expression by 22 ± 0.04% and 25 ± 0.12% respectively compared with control under TNF-α treatment (P < 0.05).

Emerging evidence suggest that notch signaling pathway is an evolutionarily highly conserved mechanism for cell to cell communication and has been shown to regulate the differentiation and growth of carcinoid tumor cells [45, 49, 50]. Furthermore, over-expression of Notch-1 has been found led to the acquisition of EMT phenotype by up-regulation of mesenchymal cell markers, ZEB1, ZEB2, Snail2, and down-regulation of epithelial cell marker, E-cadherin, in pancreatic cancer cells [23]. In the present study, we demonstrated that GEN suppressed notch-1 expression significantly in HT-29 cells (P < 0.05). These data turned out that GEN can reverse EMT and induce apoptosis by impairing notch1 activation which then hindered its downstream target NF-κB p65 in HT-29 cells.

It has been confirmed that the genes such as anti-apoptotic (B-cell lymphoma-2, Bcl-2) and pro-apoptotic (Bax) are important regulators of apoptosis in colon cancer cells [33, 35]. The ratio between pro- and anti-apoptotic Bcl-2 proteins determines whether cells survive or die [51]. Bcl-2 is a target gene of NF-κB which inhibits apoptosis through interfering with caspase-8 activation [35]. Moreover, the NF-κB serves as a link between Bcl-2 expression and cell anti-apoptotic capacity [52]. In this study, the Bcl-2 was found decreased and Bax was increased as a result was the significant increased of Bax/Bcl-2 in HT-29 cells when treated by GEN. Similar results were obtained when the cells were treated by TNF-α. These data suggested a marked apoptosis induced by both GEN and TNF-α.

Caspase-3 which can be activated by caspase-8 is a key executioner of cell apoptosis and is one of the enzymes known for the activation of different proteins that lead to programmed cell death [53]. Our results further found that the caspase-8 and caspase-3 expression was significantly increased by GEN. Taken together, our results suggest that GEN induces apoptosis of HT-29 cells via EMT and notch1 signal pathway (Fig. 7). In particular, GEN reverse the EMT by promoting E-cadherin expression and inhibiting N-cadherin expression, combine with the regulations of EMT makers such as Snail1, Snail2/slug, ZEB1, ZEB2, FOXC2 and TWIST1. Furthermore, GEN promotes Bax/Bcl-2 and caspase activity by inhibiting notch-1 pathway. And the notch-1 reduction leads to the inhibition of both p-NF-κB and NF-κB expression which again results in a negative regulation of EMT (Fig, 7).
Fig. 7

Pathways involved in apoptotic and EMT effect by genistein in HT-29 cells. Genistein reverse the EMT by promoting E-cadherin expression and inhibiting N-cadherin expression; combine with the regulations of EMT makers, Snail2/slug, ZEB1, and TWIST1. Genistein promotes Bax/Bcl-2 and caspase-8 activity by inhibiting notch-1. The notch-1 reduction leads to the inhibition of both p-NF-κB and NF-κB expression results in a reduction of EMT

Conclusion

To our knowledge, no researches about the effect of GEN on EMT of colon cancer cells have been published. In this paper, we first demonstrated a novel mechanism on anticancer of GEN: the reversal of EMT. Over the years, cancer therapy had witnessed many exciting developments, but cure of cancer has still remained as complex as the disease itself. TNF-α can induce the apoptosis while with potentially induction of invasion and metastasis of colon cancer cells. GEN, however, was found by our results not only can induce the apoptosis but also can reverse the EMT of the cells. These results provide important new insights into the potential value of GEN as an anti-tumor agent.

Abbreviations

AO/EB: 

Acridine orange and ethidium bromide

DAPI: 

4′,6-diamidino-2-phenylindole

DMSO: 

Dimethylsulfoxide

ELISA: 

Enzyme linked immunosorbent assay

EMT: 

Epithelial mesenchymal transition

FCM: 

Flow Cytometry

GEN: 

Genistein

MTT: 

3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyl tetrazolium

NF-κB: 

Nuclear factor-kappaB

TNF-α: 

Tumor necrosis factor-α

Declarations

Acknowledgments

We thank the National Natural Science Foundation of China (NSFC) for the funding support. And we thank all the colleagues and collaborators who helped with this work.

Funding

This work was supported by the National Natural Science Foundation of China (No. 31471591). The funding bodies have no roles in the design of the study and collection analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

Authors’ contributions

PPZ and WRC: Carried out and design the experiments, and participated in the preparation of figures. CLW and ZBH: Designed hypothesizes and the experiments, and participated in the data analysis and preparation of the manuscript. WTQ: Envisioned the study, participated in its design, coordination and final manuscript preparation. AKL: Participated in the design of experiment and final manuscript preparation. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The experiments in this paper have no animal and human beings were included. And the study received local approval of the Ethic Committee of Academy of State Administration of Grain.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Cereals & Oils Nutrition Research Group, Academy of State Administration of Grain (ASAG)
(2)
Key Laboratory of Food Safety and Sanitation, Ministry of Education, College of Food Engineering and Biotechnology, Tianjin University of Science and Technology
(3)
Institue for In Vitro Diagnostic Reagents Control, the National Institutes for food and drug Control (NIFDC)

References

  1. Pudenz M, et al. Impact of soy isoflavones on the epigenome in cancer prevention. Nutrients. 2014;6(10):4218–72.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Torre LA, et al. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomark Prev. 2016;25(1):16–27.View ArticleGoogle Scholar
  3. Qi WT, et al. Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. BMC Cancer. 2011;11(1):219–28.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Wang Z, et al. Genistein increases gene expression by demethylation of WNT5a promoter in colon cancer cell line SW1116. Anticancer Res. 2010;30(11):4537–45.PubMedGoogle Scholar
  5. Takahashi M, et al. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci. 2004;95(6):475–80.View ArticlePubMedGoogle Scholar
  6. Cottonham CL, et al. MiR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem. 2010;285(46):35293–302.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Bates RC, et al. Tumor nectosis factor-alpha stimulates the epithelial to mesenchymal transition of human colonic organoids. Mol Biol Cell. 2003;14(5):1790–800.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Wang H, Chen H, et al. Genistein Affects Histone Modifications on Dickkopf-Related Protein 1 (DKK1) Gene in SW480 Human Colon Cancer Cell Line. Plos One. 2012;7(7):e40955.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Mahmoud AM, et al. Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem. 2014;140(3):116–32.View ArticleGoogle Scholar
  10. Zhang YF, et al. Positive effects of soy isoflavone food on survival of breast cancer patients in China. Asian Pac J Cancer Prev. 2012;13(2):479–82.View ArticlePubMedGoogle Scholar
  11. Koehn BH, Schoenberger SP. Tumor immunotherapy: making an immortal army. Nat Med. 2009;15(7):731–2.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Techasen A, et al. Tumor necrosis factor-α (TNF-α) stimulates the epithelial-mesenchymal transition regulator snail in cholangiocarcinoma. Med Oncol. 2012;29(5):3083–91.View ArticlePubMedGoogle Scholar
  13. Dong R, et al. Role of nuclear factor kappa B and reactive oxygen species in the tumor necrosis factor-alpha-induced epithelial-mesenchymal transition of MCF-7 cells. Braz J Med Biol Res. 2007;40:1071–8.View ArticlePubMedGoogle Scholar
  14. Comijn J, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001;7(6):1267.View ArticlePubMedGoogle Scholar
  15. Peinado H, et al. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype. Nat Rev Cancer. 2007;7(6):415–28.View ArticlePubMedGoogle Scholar
  16. Puisieux A. Role of epithelial-mesenchymal transition in tumor progression. Bull Acad Natl Med. 2009 Dec;193(9):2017–32.PubMedGoogle Scholar
  17. Dai W, et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: partial mediation by the transcription factor NFAT1. Mol Carcinog. 2015;54(4):301–11.View ArticlePubMedGoogle Scholar
  18. Ha GH, et al. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett. 2013;332(1):63–73.View ArticlePubMedGoogle Scholar
  19. Zou XZ, et al. MicroRNAs-mediated epithelial-mesenchymal transition in development and disease. Cell. 2009;139(5):871–90.View ArticleGoogle Scholar
  20. Tsuji T, et al. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 2009;69:7135–9.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Polyak K, et al. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265–73.View ArticlePubMedGoogle Scholar
  22. Zhang LL, et al. A novel anti-cancer effect of genistein: reversal of epithelial mesenchymal transition in prostate cancer cells. Acta Pharmacol Sin. 2008;29(9):1060–8.View ArticlePubMedGoogle Scholar
  23. Bao B, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Letter. 2011;307(1):26–36.View ArticleGoogle Scholar
  24. Lee GA, et al. Roles of Dietary Phytoestrogens on the Regulation of Epithelial-Mesenchymal Transition in Diverse Cancer Metastasis. Toxins (Basel). 2016;8(6):162–79.View ArticleGoogle Scholar
  25. Kurrey NK, et al. Snail and slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol. 2005;97(1):155–65.View ArticlePubMedGoogle Scholar
  26. Martin TA, et al. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol. 2005;12(6):488–96.View ArticlePubMedGoogle Scholar
  27. Cong N, et al. Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/β-catenin pathway by targeting the E-cadherin reperssors ZEB1/ZEB2 in gastric adenocarcinoma. Oncol Rep. 2013;29(4):1579–87.View ArticlePubMedGoogle Scholar
  28. Wang H, et al. Epithelial-mesenchymal transition (EMT) induced by TNF-α requires AKT/GSK-3β-mediated stabilization of snail in colorectal cancer. PLoS One. 2013;8(2):e56664.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Chua HL, et al. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene. 2007;26(5):711–24.View ArticlePubMedGoogle Scholar
  30. Maier HJ, et al. NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer Letter. 2010;295(295):214–28.View ArticleGoogle Scholar
  31. Xiao G, et al. NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100. Mol Cell. 2001;7(2):401–9.View ArticlePubMedGoogle Scholar
  32. Dong W, et al. Exposure to TNF-α combined with TGF-β induces carcinogenesis in vitro via NF-κB/twist axis. Oncol Rep. 2017;37(3):1873–88.View ArticlePubMedGoogle Scholar
  33. Yang J, et al. Prevention of apoptosis by Bcl-2: release of cytochromec from mitochondria blocked. Science. 1997;275(5303):1129–32.View ArticlePubMedGoogle Scholar
  34. De GF, et al. The permeability transition pore signals apoptosis by directing Bax translocation and multimerization. FASEB Joumal. 2002;16(6):607–9.Google Scholar
  35. Kim BM, et al. Combined treatment with the Cox-2 inhibitor niflumic acid and PPARc ligand ciglitazone induces ER stress/caspase-8-mediated apoptosis in human lung cancer cells. Cancer Lett. 2011;300(2):134–44.View ArticlePubMedGoogle Scholar
  36. Leong KH, et al. Cycloart-24-ene-26-ol-3-one, a new Cycloartane isolated from leaves of Aglaia Exima triggers tumour necrosis factor-receptor 1-mediated caspase-dependent apoptosis in colon cancer cell line. PLoS One. 2016;11(4):e0152652.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Kuntz S, et al. Comparative analysis of the effect of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr. 1999;38(3):133–42.View ArticlePubMedGoogle Scholar
  38. Sandra RL, et al. The effects of genistein and daidzein on cell proliferation kinetics in HT29 colon cancer cells: the expression of CTNNBIP1 (β-catenin), APC (adenomatous polyposis coli) and BIRC5 (survivin). Hum Cell. 2014;27(2):78–84.View ArticleGoogle Scholar
  39. Kaufmann SH, et al. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 2001;11(12):526–34.View ArticlePubMedGoogle Scholar
  40. Cappellesso R, et al. The prognostic role of the epithelial-mesenchymal transition markers E-cadherin and slug in laryngeal squamous cell carcinoma. Histopathology. 2015;67(4):491–500.View ArticlePubMedGoogle Scholar
  41. Seton-Rogers S. Epithelial-mesenchymal transition: untangling EMT's functions. Nat rev. Cancer. 2016;16(1):1.PubMedGoogle Scholar
  42. Csiszar A, et al. Characterization of cytokine mRNA expression in tumor-infiltrating mononuclear cells and tumor cells freshly isolated from human colorectal carcinomas. Eur Cytokine Netw. 2001;12(1):87–96.PubMedGoogle Scholar
  43. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29.View ArticlePubMedGoogle Scholar
  44. Yang C, et al. Downregulation of Foxc2 enhances apoptosis induced by 5-fluorouracil through activation of MAPK and AKT pathways in colorectal cancer. Oncol Lett. 2016;11(2):1549–54.PubMedPubMed CentralGoogle Scholar
  45. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene. 1999;18(49):6910–24.View ArticlePubMedGoogle Scholar
  46. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Investig. 2001;107(1):7–11.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Ghosh S, et al. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–60.View ArticlePubMedGoogle Scholar
  48. Ling H, et al. 6-Shogaol, an active constituent of ginger, inhibits breast cancer cell invasion by reducing matrix metalloproteinase-9 expression via blockade of nuclear factor-κB activation. Br J Pharmacol. 2010;161(8):1763–77.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Artavanis TS, et al. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–861.View ArticleGoogle Scholar
  50. Wang Z, et al. Exploitation of the notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 2008;28(6):3621–30.PubMedGoogle Scholar
  51. Hanson CJ, et al. The cellular concentration of Bcl-2 determines its pro- or anti-apoptotic effect. Cell Calcium. 2008;44(3):243–58.View ArticlePubMedGoogle Scholar
  52. Sharifi AM, et al. Involvement of caspase-8, −9, and −3 in high glucose-induced apoptosis in PC12 cells. Neurosci Lett. 2009;459(2):47–51.View ArticlePubMedGoogle Scholar
  53. Guillermo LV, et al. Targeting caspases in intracellular protozoan infections. Immunopharmacol Immunotoxicol. 2009;31(2):159–73.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement